Pharmaceutical composition for the prevention or treatment of nicotine addiction and withdrawal symptoms including miRNA
AssigneeKorea Institute of Science and Technology
InventorsHeh-In Im, Byung Sun Kim
Life of this patent
Estimating the term…
Abstract
Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.
Claims2
A method for screening a candidate for treating nicotine addiction or withdrawal symptoms comprising:
- a) treating an animal model having nicotine addiction or withdrawal symptoms with a candidate;
- b) measuring the expression level of miR-137 in the animal model treated with the candidate;
- c) determining whether the candidate increases the expression level of miR-137 compared to an untreated control;
- and
- d) administering the candidate containing miR-137 to a patient for treating the nicotine addition or the withdrawal symptoms if the candidate increases the expression level of miR-137 compared to the untreated control.
Dependencies are inferred from the claim text.